The HHS Office of Inspector General (OIG) issued Advisory Opinion No. 24-03 (opinion) on June 12 regarding assistance for certain travel, lodging, meals, and associated expenses for qualifying patients receiving a gene therapy product (product) manufactured by the "requestor." Specifically, the requestor inquired as to whether the proposed "arrangement," as discussed below, would warrant sanctions under Sections 1128A(a)(7), 1128B(b) 1128A(a)(5), or 1128(b)(7) of the Social Security Act (SSA), as they relate to the federal Anti-Kickback Statute (AKS) and the beneficiary inducements civil monetary penalties (CMP).